Artios Pharma Limited

Conditions look ripe for an uptick in M&A this year after a fairly quiet 2022, while other types of strategic deals are also expected to increase in the face of a challenging funding situation for bio

The first half of 2022 saw the NASDAQ Biotechnology Index lose a quarter of its value. Despite a tentative recovery since then, the IPO window is barely ajar and valuations remain well below the highs

Merck KGaA is hoping to position itself as a leader among companies looking to develop next-generation PARP inhibitors by teaming up with Italy's Nerviano Medical Sciences . The German group has ink

Repare Therapeutics, Inc. got ample upfront cash, significant earnout potential, the chance to opt back in on US commercialization and, according to analysts, strong validation for its DNA damage rep